Source Count: 11 | Weighted Score: 30 | Source Confidence: [4/5] | Primary Tier: 1 | Last Updated: June 15, 2025
Keywords: cancer genomics, precision oncology, tumor sequencing, oncogene, tumor suppressor, somatic mutation, driver mutation, passenger mutation, TCGA, Cancer Genome Atlas, immunotherapy, PD-1, checkpoint inhibitor, liquid biopsy, tumor mutational burden
Category Tags: cancer-genomics, precision-medicine, molecular-biology, oncology, genomics
Cross-References: Z_2_05 — Gene Therapy · Z_1_08 — Transposons & Mobile Genetic Elements · X_3_08 — Cancer Research History

QUICK SUMMARY

Cancer genomics — the comprehensive analysis of the genetic alterations that drive cancer initiation, progression, and resistance to therapy — has transformed oncology from a tissue-of-origin classification system into a molecularly defined discipline. The foundational discovery that cancer is fundamentally a disease of the genome dates to Theodor Boveri's chromosome theory of cancer (1914), but the modern field emerged with the identification of the first human oncogene, RAS, through transfection experiments by Robert Weinberg and colleagues at MIT in 1982, and the cloning of the first tumor suppressor gene, RB1 (retinoblastoma), by Stephen Friend et al. in 1986. The Cancer Genome Atlas (TCGA, 2006–2018), a $375 million joint NCI/NHGRI project, systematically characterized the genomic landscapes of 33 cancer types across more than 11,000 tumors, identifying approximately 300 driver genes and revealing that most cancers harbor 2–8 driver mutations amid thousands of passenger mutations. This knowledge has enabled precision oncology — treatment selection based on tumor molecular profiles rather than tissue histology alone. Landmark successes include imatinib (Gleevec) for BCR-ABL-positive chronic myeloid leukemia (converting a fatal disease into a manageable chronic condition), trastuzumab (Herceptin) for HER2-amplified breast cancer, and immune checkpoint inhibitors (anti-PD-1/PD-L1 antibodies) whose efficacy correlates with tumor mutational burden (TMB). Liquid biopsy — detection of circulating tumor DNA (ctDNA) in blood samples — is emerging as a non-invasive tool for cancer diagnosis, treatment monitoring, and early detection.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

• KEY FINDING The Cancer Genome Atlas (TCGA), active from 2006 to 2018, characterized the genomic, epigenomic, transcriptomic, and proteomic landscapes of 33 cancer types across 11,328 tumors — the project identified approximately 300 genes that, when mutated, drive cancer development (driver genes), as well as recurrent copy number alterations, gene fusions, and epigenetic modifications; key pan-cancer publications appeared in Cell (2018)
• Robert Weinberg and colleagues at MIT identified the first human oncogene through DNA transfection experiments in 1982 — the transforming gene from human bladder carcinoma cell lines was identified as a mutated version of the HRAS gene, with a single point mutation (glycine to valine at codon 12) sufficient to convert the normal RAS proto-oncogene into a constitutively active oncogene
• The two-hit hypothesis of tumor suppressor gene inactivation, proposed by Alfred Knudson in 1971 based on statistical analysis of retinoblastoma incidence patterns, was confirmed when the RB1 gene was cloned by Stephen Friend, Robert Weinberg, and colleagues in 1986 — establishing the paradigm that loss of function of both alleles of a tumor suppressor gene is typically required for cancer development
• KEY FINDING Imatinib mesylate (Gleevec/STI-571), a small-molecule inhibitor of the BCR-ABL tyrosine kinase, was approved by the FDA in May 2001 for chronic myeloid leukemia (CML) — it transformed CML from a disease with median survival of 3–5 years to one with 10-year survival rates exceeding 80%, and became the paradigm for molecularly targeted cancer therapy
• Immune checkpoint inhibitors — monoclonal antibodies blocking the PD-1/PD-L1 axis (nivolumab, pembrolizumab) or CTLA-4 (ipilimumab) — have produced durable responses in multiple cancer types; James Allison and Tasuku Honjo received the 2018 Nobel Prize in Physiology or Medicine for their discoveries of CTLA-4 and PD-1 checkpoint pathways, respectively

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

• Tumor mutational burden (TMB) — the total number of somatic mutations per megabase of coding genome — has emerged as a biomarker predicting response to immune checkpoint inhibitors: tumors with high TMB (typically >10 mutations/Mb) generate more neoantigens recognizable by T cells, increasing the probability of immune-mediated tumor rejection; the FDA approved pembrolizumab for TMB-high solid tumors (agnostic of tissue of origin) in June 2020
• Liquid biopsy technology — detection and analysis of cell-free circulating tumor DNA (ctDNA) in blood plasma — can identify tumor-specific mutations, monitor treatment response, detect minimal residual disease after surgery, and identify resistance mutations without invasive tissue biopsy; the Guardant360 and FoundationOne Liquid CDx assays received FDA approval in 2020 and 2020 respectively
• Intratumor heterogeneity — the presence of genetically distinct subclones within a single tumor — has been demonstrated by multi-region sequencing studies (e.g., the TRACERx consortium for lung cancer, led by Charles Swanton at the Francis Crick Institute) to be a major driver of treatment resistance and relapse; tumors are not genetically uniform but are evolving ecosystems
• The "long tail" problem in cancer genomics: while a few genes are recurrently mutated across many cancer types (TP53 in ~50%, KRAS in ~25%, PIK3CA in ~15%), the majority of cancer driver genes are mutated in fewer than 5% of cases — making clinical trial design and drug development for rare driver mutations economically challenging

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

• Multi-cancer early detection (MCED) blood tests — exemplified by GRAIL's Galleri test, which analyzes cell-free DNA methylation patterns to detect over 50 cancer types from a single blood draw — have shown promising performance in prospective studies (specificity >99.5%, overall sensitivity ~51.5% across all stages), but their impact on cancer mortality reduction has not yet been demonstrated in randomized trials (the NHS-Galleri trial in the UK, enrolling 140,000 participants, is ongoing)
• The concept of "cancer interception" — intervening at premalignant stages based on genomic risk signatures before invasive cancer develops — is theoretically compelling but faces challenges including the high prevalence of driver mutations in normal tissues (e.g., TP53 mutations in ~2–3% of normal esophageal epithelial cells, as reported by Iñigo Martincorena et al. in Science, 2018) — suggesting that driver mutations alone are insufficient for cancer development
• Synthetic lethality approaches (e.g., PARP inhibitors in BRCA1/2-mutated cancers) represent an expanding class of genomically targeted therapies, but extending this concept to other genetic vulnerabilities beyond BRCA has proven more difficult than initially anticipated

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

• DEBUNKED The "somatic mutation theory" as the sole explanation for cancer has been challenged but not overturned — while researchers (e.g., Carlos Sonnenschein and Ana Soto, the "tissue organization field theory") argue that cancer originates from disrupted tissue architecture rather than accumulated mutations, the overwhelming weight of genomic evidence supports somatic mutations as necessary (if not always sufficient) drivers of malignant transformation
• Claims that comprehensive tumor sequencing will reliably identify effective treatments for all cancer patients — in practice, only 10–15% of patients with advanced solid tumors who undergo genomic profiling are matched to molecularly targeted therapies, and of those, only a fraction achieve durable responses

Counter-Arguments & Criticisms

• Precision oncology has been criticized for benefiting primarily patients with common driver mutations in well-funded cancer types, while leaving the majority of patients without actionable genomic findings — Vinay Prasad and colleagues have argued that the benefit of large-panel genomic testing in unselected cancer populations is modest relative to cost
• The cost of genomic testing and targeted therapies creates equity concerns — many targeted agents cost $10,000–$15,000 per month, and genomic sequencing infrastructure is concentrated in high-income countries; global access to precision oncology remains profoundly unequal
• Normal tissue mutation studies have complicated the driver mutation paradigm — Martincorena et al. (2015, 2018) showed that clonally expanded somatic mutations (including in canonical cancer genes like TP53, NOTCH1, and PIK3CA) are ubiquitous in sun-exposed skin, esophagus, and other normal tissues of healthy individuals, raising questions about why most mutated clones never progress to cancer

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Weinberg, Robert | 2014 | ∅ | The Biology of Cancer | ∅ | ∅ | New York: Garland Science | 2nd | isbn:9780815342205 | ∅ | ∅ | ∅
2. Cancer Genome Atlas Research Network | 2008 | "Comprehensive Genomic Characterization Defines Human Glioblastoma Genes and Core Pathways" | Nature | ∅ | 455.7216::1061–1068 | ∅ | ∅ | doi:10.1038/nature07385 | ∅ | ∅ | ∅
3. Hoadley, Katherine, et al | 2018 | "Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer" | Cell | ∅ | 173.2::291–304 | ∅ | ∅ | doi:10.1016/j.cell.2018.03.022 | ∅ | ∅ | ∅
4. Knudson, Alfr (ed.) | 1971 | "Mutation and Cancer: Statistical Study of Retinoblastoma" | Proceedings of the National Academy of Sciences | ∅ | 68.4::820–823 | ∅ | ∅ | doi:10.1073/pnas.68.4.820 | ∅ | ∅ | ∅
5. Druker, Brian, et al | 2001 | "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia" | New England Journal of Medicine | ∅ | 344.14::1031–1037 | ∅ | ∅ | doi:10.1056/NEJM200104053441401 | ∅ | ∅ | ∅
6. Topalian, Suzanne, et al | 2012 | "Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer" | New England Journal of Medicine | ∅ | 366.26::2443–2454 | ∅ | ∅ | doi:10.1056/NEJMoa1200690 | ∅ | ∅ | ∅
7. Martincorena, Iñigo, et al | 2018 | "Somatic Mutant Clones Colonize the Human Esophagus with Age" | Science | ∅ | 362.6417::911–917 | ∅ | ∅ | doi:10.1126/science.aau3879 | ∅ | ∅ | ∅
8. Swanton, Charles, et al | 2017 | "Tracking the Evolution of Non-Small-Cell Lung Cancer" | New England Journal of Medicine | ∅ | 376.22::2109–2121 | ∅ | ∅ | doi:10.1056/NEJMoa1616288 | ∅ | ∅ | ∅
9. Wan, Jonathan, et al | 2017 | "Liquid Biopsies Come of Age: Towards Implementation of Circulating Tumour DNA" | Nature Reviews Cancer | ∅ | 17.4::223–238 | ∅ | ∅ | doi:10.1038/nrc.2017.7 | ∅ | ∅ | ∅
10. Vogelstein, Bert, et al | 2013 | "Cancer Genome Landscapes" | Science | ∅ | 339.6127::1546–1558 | ∅ | ∅ | doi:10.1126/science.1235122 | ∅ | ∅ | ∅
11. Alexandrov, Ludmil B., et al | 2013 | "Signatures of mutational processes in human cancer" | Nature | ∅ | 500.7463::415–421 | ∅ | ∅ | doi:10.1038/nature12477 | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: June 15, 2025